Identification of Opioid Ligands Possessing Mixed μ Agonist/δ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydropmorphone

Subramaniam Ananthan, Naveen K. Khare, Surendra K. Saini, Lainne E. Seitz, Jeffrey L. Bartlett, Peg Davis, Christina M. Dersch, Frank Porreca, Richard B. Rothman, Edward J. Bilsky

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

A series of pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone (7a-k) were synthesized and evaluated for binding affinity at the opioid δ/μ and κ receptors in brain membranes using radioligand binding assays and for functional activity in vitro using [ 35S]GTP-γ-S binding assays in brain tissues and bioassays using guinea pig ileum (GPI) and mouse vas deferens (MVD) smooth muscle preparations. The pyridine ring unsubstituted pyridomorphinans possessing the oxymorphone and hydromorphone framework displayed nearly equal binding affinity at the μ and δ receptors. Their affinities at the κ site were nearly 10-fold less than their binding affinities at the μ and δ sites. Introduction of aryl substituents at the 5′-position on the pyridine ring improved the binding affinity at the δ site while decreasing the binding affinity at the μ site. Nearly all of the ligands possessing an N-methyl group at the 17-position with or without a hydroxyl group at the 14-position of the morphinan moiety displayed agonist activity at the μ receptor with varying potencies and efficacies. In the [ 35S]GTP-γ-S binding assays, most of these pyridomorphinans were devoid of any significant agonist activity at the δ and κ receptors but displayed moderate to potent antagonist activity at the δ receptors. In antinociceptive evaluations using the warm-water tail-withdrawal assay in mice, the pyridomorphinans produced analgesic effects with varying potencies and efficacies when administered by the intracerebroventricular route. Among the ligands studied, the hydromorphone-derived 4-chlorophenylpyridomorphinan 7h was identified as a ligand possessing a promising profile of mixed μ agonist/δ antagonist activity in vitro and in vivo. In a repeated administration paradigm in which the standard μ agonist morphine produces significant tolerance, repeated administration of the μ agonist/δ antagonist ligand 7h produced no tolerance. These results indicate that appropriate molecular manipulations of the morphinan templates could provide ligands with mixed μ agonist/δ antagonist profiles and such ligands may have the potential of emerging as novel analgesic drugs devoid of tolerance, dependence, and related side effects.

Original languageEnglish (US)
Pages (from-to)1400-1412
Number of pages13
JournalJournal of Medicinal Chemistry
Volume47
Issue number6
DOIs
StatePublished - Mar 11 2004

Fingerprint

Oxymorphone
Naloxone
Opioid Analgesics
Hydromorphone
Ligands
Assays
Morphinans
Guanosine Triphosphate
Analgesics
Brain
Drug Tolerance
Radioligand Assay
Vas Deferens
Bioassay
Opioid Receptors
Ileum
Biological Assay
Hydroxyl Radical
Morphine
Smooth Muscle

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Identification of Opioid Ligands Possessing Mixed μ Agonist/δ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydropmorphone. / Ananthan, Subramaniam; Khare, Naveen K.; Saini, Surendra K.; Seitz, Lainne E.; Bartlett, Jeffrey L.; Davis, Peg; Dersch, Christina M.; Porreca, Frank; Rothman, Richard B.; Bilsky, Edward J.

In: Journal of Medicinal Chemistry, Vol. 47, No. 6, 11.03.2004, p. 1400-1412.

Research output: Contribution to journalArticle

Ananthan, Subramaniam ; Khare, Naveen K. ; Saini, Surendra K. ; Seitz, Lainne E. ; Bartlett, Jeffrey L. ; Davis, Peg ; Dersch, Christina M. ; Porreca, Frank ; Rothman, Richard B. ; Bilsky, Edward J. / Identification of Opioid Ligands Possessing Mixed μ Agonist/δ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydropmorphone. In: Journal of Medicinal Chemistry. 2004 ; Vol. 47, No. 6. pp. 1400-1412.
@article{4b65db6543cd4788b0cb24100f07e9e5,
title = "Identification of Opioid Ligands Possessing Mixed μ Agonist/δ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydropmorphone",
abstract = "A series of pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone (7a-k) were synthesized and evaluated for binding affinity at the opioid δ/μ and κ receptors in brain membranes using radioligand binding assays and for functional activity in vitro using [ 35S]GTP-γ-S binding assays in brain tissues and bioassays using guinea pig ileum (GPI) and mouse vas deferens (MVD) smooth muscle preparations. The pyridine ring unsubstituted pyridomorphinans possessing the oxymorphone and hydromorphone framework displayed nearly equal binding affinity at the μ and δ receptors. Their affinities at the κ site were nearly 10-fold less than their binding affinities at the μ and δ sites. Introduction of aryl substituents at the 5′-position on the pyridine ring improved the binding affinity at the δ site while decreasing the binding affinity at the μ site. Nearly all of the ligands possessing an N-methyl group at the 17-position with or without a hydroxyl group at the 14-position of the morphinan moiety displayed agonist activity at the μ receptor with varying potencies and efficacies. In the [ 35S]GTP-γ-S binding assays, most of these pyridomorphinans were devoid of any significant agonist activity at the δ and κ receptors but displayed moderate to potent antagonist activity at the δ receptors. In antinociceptive evaluations using the warm-water tail-withdrawal assay in mice, the pyridomorphinans produced analgesic effects with varying potencies and efficacies when administered by the intracerebroventricular route. Among the ligands studied, the hydromorphone-derived 4-chlorophenylpyridomorphinan 7h was identified as a ligand possessing a promising profile of mixed μ agonist/δ antagonist activity in vitro and in vivo. In a repeated administration paradigm in which the standard μ agonist morphine produces significant tolerance, repeated administration of the μ agonist/δ antagonist ligand 7h produced no tolerance. These results indicate that appropriate molecular manipulations of the morphinan templates could provide ligands with mixed μ agonist/δ antagonist profiles and such ligands may have the potential of emerging as novel analgesic drugs devoid of tolerance, dependence, and related side effects.",
author = "Subramaniam Ananthan and Khare, {Naveen K.} and Saini, {Surendra K.} and Seitz, {Lainne E.} and Bartlett, {Jeffrey L.} and Peg Davis and Dersch, {Christina M.} and Frank Porreca and Rothman, {Richard B.} and Bilsky, {Edward J.}",
year = "2004",
month = "3",
day = "11",
doi = "10.1021/jm030311v",
language = "English (US)",
volume = "47",
pages = "1400--1412",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Identification of Opioid Ligands Possessing Mixed μ Agonist/δ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydropmorphone

AU - Ananthan, Subramaniam

AU - Khare, Naveen K.

AU - Saini, Surendra K.

AU - Seitz, Lainne E.

AU - Bartlett, Jeffrey L.

AU - Davis, Peg

AU - Dersch, Christina M.

AU - Porreca, Frank

AU - Rothman, Richard B.

AU - Bilsky, Edward J.

PY - 2004/3/11

Y1 - 2004/3/11

N2 - A series of pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone (7a-k) were synthesized and evaluated for binding affinity at the opioid δ/μ and κ receptors in brain membranes using radioligand binding assays and for functional activity in vitro using [ 35S]GTP-γ-S binding assays in brain tissues and bioassays using guinea pig ileum (GPI) and mouse vas deferens (MVD) smooth muscle preparations. The pyridine ring unsubstituted pyridomorphinans possessing the oxymorphone and hydromorphone framework displayed nearly equal binding affinity at the μ and δ receptors. Their affinities at the κ site were nearly 10-fold less than their binding affinities at the μ and δ sites. Introduction of aryl substituents at the 5′-position on the pyridine ring improved the binding affinity at the δ site while decreasing the binding affinity at the μ site. Nearly all of the ligands possessing an N-methyl group at the 17-position with or without a hydroxyl group at the 14-position of the morphinan moiety displayed agonist activity at the μ receptor with varying potencies and efficacies. In the [ 35S]GTP-γ-S binding assays, most of these pyridomorphinans were devoid of any significant agonist activity at the δ and κ receptors but displayed moderate to potent antagonist activity at the δ receptors. In antinociceptive evaluations using the warm-water tail-withdrawal assay in mice, the pyridomorphinans produced analgesic effects with varying potencies and efficacies when administered by the intracerebroventricular route. Among the ligands studied, the hydromorphone-derived 4-chlorophenylpyridomorphinan 7h was identified as a ligand possessing a promising profile of mixed μ agonist/δ antagonist activity in vitro and in vivo. In a repeated administration paradigm in which the standard μ agonist morphine produces significant tolerance, repeated administration of the μ agonist/δ antagonist ligand 7h produced no tolerance. These results indicate that appropriate molecular manipulations of the morphinan templates could provide ligands with mixed μ agonist/δ antagonist profiles and such ligands may have the potential of emerging as novel analgesic drugs devoid of tolerance, dependence, and related side effects.

AB - A series of pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone (7a-k) were synthesized and evaluated for binding affinity at the opioid δ/μ and κ receptors in brain membranes using radioligand binding assays and for functional activity in vitro using [ 35S]GTP-γ-S binding assays in brain tissues and bioassays using guinea pig ileum (GPI) and mouse vas deferens (MVD) smooth muscle preparations. The pyridine ring unsubstituted pyridomorphinans possessing the oxymorphone and hydromorphone framework displayed nearly equal binding affinity at the μ and δ receptors. Their affinities at the κ site were nearly 10-fold less than their binding affinities at the μ and δ sites. Introduction of aryl substituents at the 5′-position on the pyridine ring improved the binding affinity at the δ site while decreasing the binding affinity at the μ site. Nearly all of the ligands possessing an N-methyl group at the 17-position with or without a hydroxyl group at the 14-position of the morphinan moiety displayed agonist activity at the μ receptor with varying potencies and efficacies. In the [ 35S]GTP-γ-S binding assays, most of these pyridomorphinans were devoid of any significant agonist activity at the δ and κ receptors but displayed moderate to potent antagonist activity at the δ receptors. In antinociceptive evaluations using the warm-water tail-withdrawal assay in mice, the pyridomorphinans produced analgesic effects with varying potencies and efficacies when administered by the intracerebroventricular route. Among the ligands studied, the hydromorphone-derived 4-chlorophenylpyridomorphinan 7h was identified as a ligand possessing a promising profile of mixed μ agonist/δ antagonist activity in vitro and in vivo. In a repeated administration paradigm in which the standard μ agonist morphine produces significant tolerance, repeated administration of the μ agonist/δ antagonist ligand 7h produced no tolerance. These results indicate that appropriate molecular manipulations of the morphinan templates could provide ligands with mixed μ agonist/δ antagonist profiles and such ligands may have the potential of emerging as novel analgesic drugs devoid of tolerance, dependence, and related side effects.

UR - http://www.scopus.com/inward/record.url?scp=12144289451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144289451&partnerID=8YFLogxK

U2 - 10.1021/jm030311v

DO - 10.1021/jm030311v

M3 - Article

C2 - 14998329

AN - SCOPUS:12144289451

VL - 47

SP - 1400

EP - 1412

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 6

ER -